1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Red tape hurt vaccine sales says Serum as it readies new intranasal trivalent flu product

 
• By Anju Ghangurde

Serum Institute of India, the world's largest producer of the measles and diphtheria-tetanus-pertussis group of vaccines, is developing an intranasal trivalent influenza vaccine, but claims that government red tape has hurt the prospects of its already launched cut-price, indigenously developed intranasal H1N1 flu vaccine, Nasovac.

Serum Institute of India, the world's largest producer of the measles and diphtheria-tetanus-pertussis group of vaccines, is developing an intranasal trivalent influenza vaccine, but claims that government red tape has hurt the prospects of its already launched cut-price, indigenously developed intranasal H1N1 flu vaccine, Nasovac.

Serum said that the new intranasal trivalent vaccine will offer protection against the H1N1, H3N2 and B/Brisbane viruses, in line with World Health Organisation recommendations, and that the company

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 
• By Jessica Merrill

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

More from Therapeutic Category

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.